Lilly’s Next-Generation Obesity Shot Clears Another Hurdle

Summary

Bloomberg reporter Madison Muller discusses Eli Lilly's next-generation weight loss shot retatrutide, which cleared a cardiovascular safety hurdle and is on track for an FDA filing in early 2027. The conversation covers retatrutide's triple-hormone mechanism and potential blockbuster status, the competitive landscape with Novo Nordisk's popular oral Wegovy pill, insurance challenges, and recent Medicare coverage expansion.

• Lilly's retatrutide shows up to 30% weight loss and liver benefits, with black market demand signaling strong interest.
• Regulatory filing for retatrutide delayed to Q1 2027 due to a large data package, slightly later than analysts expected.
• Novo Nordisk's oral Wegovy pill is highlighted as a huge product helping the company recover ground against Lilly.
• Insurance coverage remains a barrier, but Medicare now covers weight loss drugs for 65+ with certain conditions, potentially opening access to millions.
• Compounded versions of weight loss drugs have become less price-competitive as brand-name cash pay costs dropped to around $200/month.
• Lilly's oral drug Found Dayo and Novo's pill are both selling well, though long-term pill vs. shot dynamics remain uncertain.